Even when researchers removed blurry or low-quality scans, the link between IGF-I and muscle energy recovery stayed strong — so the finding is reliable.
Scientific Claim
In obese adults with reduced GH, the improvement in phosphocreatine recovery after tesamorelin treatment was not significantly affected by the quality of the magnetic resonance spectroscopy scans, as sensitivity analyses excluding low-quality data still showed significant IGF-I–ViPCr associations.
Original Statement
“Sensitivity analyses using higher quality scans only (n = 15 pairs) confirmed the significant association between increases in IGF-I and improvement in ViPCr (R=0.61; P=.02).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The sensitivity analysis is reported with statistical values and correctly framed as confirmation of the association. No overstatement is present.
Evidence from Studies
Supporting (1)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
The study found that when obese people with low growth hormone took tesamorelin, their muscle energy recovery improved, and this improvement was linked to higher IGF-I levels — even after accounting for other factors, so it’s unlikely that scan quality messed up the results.